Tandem Diabetes Q1 revenue $186M, up 14% YoY; net loss $(49.1M)

TANDEM DIABETES CARE INC

2023-Q1 EPS reported -$1.92 revenue$169,383,000

Revenue $186.0M (+14% YoY); GAAP net loss $(49.1M) or $(0.75) per share.
Non-GAAP adjusted EBITDA loss $(7.3M) vs $(11.7M) loss a year ago.
Total pump shipments 37,923, up 5% YoY; U.S. sales $148.7M (+19% YoY).
International revenue $37.3M, flat YoY; currency headwinds of $4.0M.
FY 2023 revenue guidance reaffirmed: $790M-$810M; expects gross margin 49-50%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.